2023
Diabetic Ketoacidosis Associated with Sodium‐Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases
Stamatiades G, D’Silva P, Elahee M, Viana G, Sideri-Gugger A, Majumdar S. Diabetic Ketoacidosis Associated with Sodium‐Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases. International Journal Of Endocrinology 2023, 2023: 6615624. PMID: 37441367, PMCID: PMC10335870, DOI: 10.1155/2023/6615624.Peer-Reviewed Original ResearchCommon presenting symptomAbdominal painEuglycemic DKAPresenting symptomSodium-glucose cotransporter 2 inhibitorsType 2 diabetes mellitusAverage blood glucose concentrationCases of DKAPoor food intakePoor oral intakeCotransporter 2 inhibitorsRetrospective case seriesSGLT2 inhibitor useDiabetic Ketoacidosis AssociatedPotential risk factorsBlood glucose concentrationVariety of drugsAnion gap valuesSGLT2i useDiabetes durationDiabetes mellitusDKA casesInhibitor useOral intakeCase series
2013
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013, 44: 47-58. PMID: 23354728, DOI: 10.1007/s12020-013-9884-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesGlucose loweringCurrent therapiesFree Fatty Acid Receptor AgonistsNewer incretin-based therapiesGlucose cotransporter 2 inhibitorsDurable glycemic controlCotransporter 2 inhibitorsIncretin-based therapiesType 2 diabetes therapyIndividual patient characteristicsAcid receptor agonistsNew therapeutic classDiverse patient populationsMechanism of actionInsulin useComplex regimensPatient characteristicsGlycemic controlPatient populationType 1 inhibitorNatural courseReceptor agonistClinical trialsTreatment choice